United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

Key Points

• Executive sale: United Therapeutics EVP Paul Mahon sold 8,300 shares at an average price of $497.54, totaling approximately $4.13 million. His remaining direct holdings decreased by 15.52% to 45,172 shares.
• Stock performance: UTHR traded at $494.63, below its 50-day and 200-day moving averages, with a 52-week range of $408.75 to $609.35. Institutional investors own 94.08% of the company.
• Financials and outlook: The company exceeded quarterly EPS expectations with $7.27 versus $6.86, although revenue declined 1.9% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $646.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $497.54, for a total value of $4,129,582.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $22,474,876.88. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Price Performance

Shares of UTHR traded down $2.64 during mid-day trading on Friday, reaching $494.63. 1,473,643 shares of the company's stock were exchanged, compared to its average volume of 513,087. The business's fifty day simple moving average is $516.53 and its 200-day simple moving average is $540.64. The stock has a market capitalization of $21.21 billion, a PE ratio of 17.70, a price-to-earnings-growth ratio of 2.50 and a beta of 0.56. United Therapeutics Corporation has a 52-week low of $408.75 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the firm earned $6.41 EPS. United Therapeutics's revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arjuna Capital boosted its stake in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after acquiring an additional 18 shares during the period. Sage Rhino Capital LLC raised its stake in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC raised its stake in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after acquiring an additional 24 shares during the period. Meeder Advisory Services Inc. lifted its holdings in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after purchasing an additional 26 shares during the last quarter. Finally, Kera Capital Partners Inc. lifted its holdings in United Therapeutics by 6.1% during the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company's stock valued at $279,000 after purchasing an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on UTHR shares. Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada cut their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Weiss Ratings lowered shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $646.00.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.